Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins.
Brasoveanu
L I
LI
Maio
M
M
D000230:Adenocarcinoma / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000920:Antibody-Dependent Cell Cytotoxicity; D003169:Complement Inactivator Proteins / Q000276:immunology*; D006801:Humans; D007983:Lewis Blood Group Antigens / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D003169:Complement Inactivator Proteins; D007983:Lewis Blood Group Antigens; C094162:Lewis Y antigen